Division of General Thoracic Surgery, Integrative Center of General Surgery, Gunma University Hospital, Gunma, Japan; Department of Thoracic and Visceral Organ Surgery, Gunma University, Graduate School of Medicine, Gunma, Japan.
Division of General Thoracic Surgery, Integrative Center of General Surgery, Gunma University Hospital, Gunma, Japan; Department of Thoracic and Visceral Organ Surgery, Gunma University, Graduate School of Medicine, Gunma, Japan.
J Thorac Cardiovasc Surg. 2017 Oct;154(4):1406-1417.e3. doi: 10.1016/j.jtcvs.2017.03.125. Epub 2017 Apr 5.
Stathmin 1 is a major cytosolic phosphoprotein that regulates microtubule dynamics and is associated with malignant phenotypes in various cancers, including non-small cell lung cancer. We aimed to determine differences in overall survival and disease-free proportion in patients with lung adenocarcinoma stratified by stathmin 1 tumor expression.
With the use of immunohistochemistry, stathmin 1 expression was determined in resection specimens from 303 patients with adenocarcinoma. Associations between stathmin 1 protein expression and overall and disease-free proportion were assessed (Kaplan-Meier survival curves compared with log-rank statistics). Cox proportional hazards regression determined the hazard for death stratified by stathmin 1, adjusting for clinicopathologic characteristics.
During follow-up, 74 (24.4%) recurrences and 73 (24.1%) all-cause deaths were recorded. Expressed in 53.8% of adenocarcinoma cases, overall survival and disease-free proportion were significantly worse in stathmin 1-positive patients (log-rank P < .001 and P < .001, respectively). When adjusted for clinical and pathologic factors, stathmin 1 expression was an independent prognostic variable for both overall survival (hazard ratio, 2.21; 95% confidence interval, 1.28-3.80) and disease-free proportion (hazard ratio, 2.02; 95% confidence interval, 1.13-3.63) and for disease-free proportion even in the subset of patients with stage I (hazard ratio, 2.79; 95% confidence interval, 1.07-7.27). There was no significant difference between the stathmin 1-positive patients with stage IA and patients with stage IB in overall survival (P = .975) and disease-free proportion (P = .490), respectively.
Stathmin 1 expression was an independent prognostic factor for adenocarcinoma, even when restricted to patients with early-stage cancer.
Stathmin 1 是一种主要的胞质磷酸蛋白，可调节微管动力学，并与包括非小细胞肺癌在内的各种癌症的恶性表型相关。我们旨在通过分析 Stathmin 1 肿瘤表达情况，确定肺腺癌患者的总生存率和无病比例的差异。
使用免疫组织化学方法，检测 303 例肺腺癌患者的肿瘤标本中 Stathmin 1 的表达。评估 Stathmin 1 蛋白表达与总生存率和无病比例之间的相关性（通过 Kaplan-Meier 生存曲线与对数秩检验进行比较）。Cox 比例风险回归确定了按 Stathmin 1 分层的死亡风险，同时调整了临床病理特征。
在随访期间，记录了 74 例（24.4%）复发和 73 例（24.1%）全因死亡。在 53.8%的腺癌病例中表达，Stathmin 1 阳性患者的总生存率和无病比例明显较差（对数秩检验 P<0.001 和 P<0.001）。当调整临床和病理因素时，Stathmin 1 表达是总生存率（危险比，2.21；95%置信区间，1.28-3.80）和无病比例（危险比，2.02；95%置信区间，1.13-3.63）的独立预后变量，甚至在 I 期患者亚组中也是如此（危险比，2.79；95%置信区间，1.07-7.27）。Stathmin 1 阳性的 IA 期患者与 IB 期患者的总生存率（P=0.975）和无病比例（P=0.490）无显著差异。
Stathmin 1 表达是腺癌的独立预后因素，即使限于早期癌症患者也是如此。
